Document is current
Any future updates will be listed below
-
Authors
Feliu, Jaime https://orcid.org/0000-0003-4867-1420
Jorge Fernández, Mónica
Macarulla, Teresa
Massuti, Bartomeu https://orcid.org/0000-0002-7608-3952
Albero, Ana
González González, José Federico
Quintero-Aldana, Guillermo https://orcid.org/0000-0002-1445-1887
Delgado-Mingorance, Juan Ignacio
Fernández Montes, Ana https://orcid.org/0000-0003-4630-5830
García Piernavieja, Carmen https://orcid.org/0000-0003-2147-5841
Valladares-Ayerbes, Manuel https://orcid.org/0000-0002-7950-9584
López Muñoz, Ana María https://orcid.org/0000-0002-5476-3957
Mondéjar Solís, Rebeca
Vicente, Pilar
Casado Gonzalez, Esther https://orcid.org/0000-0001-7892-034X
González Cebrián, Irene
López-Vivanco, Guillermo https://orcid.org/0000-0003-3800-6224
-
Funding
Funding for this research was provided by:
Celgene
- License Information
-
More Information
Article History
Received: 6 August 2020
Accepted: 10 December 2020
First Online: 15 January 2021
Compliance with ethical standards
:
: J. Feliu has received consulting and has had an advisory role in Amgen, Ipsen, Eisai, Merck, Roche and Novartis, has received research funding from Merck and Amgen; he has received travel and accommodation expenses from Amgen and Servier. M. Jorge Fernández has been member of the advisory boards from Amgen and Celgene; she has received speaker honorarium from Merck, Roche and Servier; she has received consulting honorarium from Lilly, she has received travel grants from Merck. T. Macarulla has played a consultant or advisory role with Amgen, Baxter, Celgene, Incyte, Q&D Therapeutics, Servier and Shire; she has received research funding from AstraZeneca, BeiGEne and Celgene. B. Massuti has been member of the advisory boards for Roche, MSD and BMS; he has received speaker honorarium from AstraZeneca, Servier, BMS and Roche; he has received research grants to institution from ISCIII; he has received travel grants from AstraZeneca and MSD. A. Albero reports no conflict of interest. J. F. González González reports no conflict of interest. G. Quintero-Aldana reports no conflict of interest. J.I. Delgado-Mingorance reports no conflict of interest. A. Fernández Montes reports no conflict of interest. C. García Piernavieja reports no conflict of interest. M. Valladares-Ayerbes has been member of the advisory boards for Merck, Amgen and Sanofi; he has received research grants to institution from Roche; he has received personal fees from Merck, Amgen and personal fees from Sanofi during the conduct of the study; he has received personal fees from Servier, personal fees from Bayer, personal fees from Celgene, outside the submitted work. A.M. López Muñoz reports no conflict of interest. R. Móndejar Solís has been member of the advisory boards for Amgen, Merck, Roche, Pfizer, Servier and Celgene; she has received speaker honorarium from Amgen, Merck, Roche, Pfizer, Servier and Celgene. P. Vicente reports no conflict of interest. E. Casado González reports no conflict of interest. I. González Cebrián has been member of the advisory board for Celgene. G. López-Vivanco reports no conflict of interest.
: The study protocol was approved by the independent ethics committee of the Ethical Research Committee of the Puerta de Hierro-Majadahonda University Hospital, and the study was conducted in compliance with the Good Clinical Practice Guidelines and in accordance with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all patients before they entered the study. The trial was registered at ClinicalTrials.gov under number NCT02391662.
